Assistant Professor, Medicine, University of Texas Medical School, San Antonio
Oncology
Dr. John C. Sarantopoulos, DO
|
|
Give Review
John C. Sarantopoulos, DO works in the field of Oncology. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". John C. Sarantopoulos, DO has written publications. He has 36 publications published with PubMed. The lastest publication is: 'Age- and sex-related differences in nuclear lipid content and nucleoside triphosphatase activity in the JCR:LA-cp corpulent rat.' John Sarantopoulos accepts Medicare.
Publications
- Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
- Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
- Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
- Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.
- Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
- Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
- Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketocona...
- Predicting success in regulatory approval from Phase I results.
- Combined autophagy and HDAC inhibition: A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDA...
- Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib...
- Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials.
- A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors.
- Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.
- Clinical Outcomes and Survival of Advanced Renal Cancer Patients in Phase I Clinical Trials.
- Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.
- A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.
- Phase 1 Dose-Escalation Study of VB-111, an Anti-Angiogenic Virotherapy, in Patients with Advanced Solid Tumors.
- Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignanc...
- Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
- Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced...
- The pim kinases: new targets for drug development.
- Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
- Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Gr...
- A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
- Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
- Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.
- RANK ligand: effects of inhibition.
- Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
- Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
- Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
- Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
- Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
- A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
- Age- and sex-related differences in nuclear lipid content and nucleoside triphosphatase activity in the JCR:LA-cp corpulent rat.
- Nuclear cholesterol content and nucleoside triphosphatase activity are altered in the JCR:LA-cp corpulent rat.
Schools
Ohio Univ Coll Of Osteo Med
Chicago Osteo Hosps amp Med Ctrs
U ChicagoSchwab Rehab Hosp Prog
George Washingotn University
Procedures Preformed
- Cervical Decompression Therapy
- Chronic Pain Management
- EMG (Electromyography)
- Joint Injection
- View All
Conditions Treated
- Arthritis
- Autonomic Disorders
- Back Pain
- Cervical Spine Myelopathy
- View All
Doctors Specialties
- Pain Medicine
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Manitoba
Hospital
-
South Texas Veterans Health Care System -
University Health System
Drug Facts
| NPI NUMBER | 1639185275 | |
| NPPES Provider LastName | SARANTOPOULOS | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 601723500 | |
| NPPES Provider State | IL | |
| Specialty Description | Physical Medicine and Rehabilitation | |
| Total Claim Count | 846.0 | |
| Distinct Opioid Count | 10.0 | |
| Opioid Claim Count | 492.0 | |
| Percent Opioid Claims | 58.16 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1639185275 |
| Last Name Of The Provider | SARANTOPOULOS |
| First Name Of The Provider | JOHN |
| View All |